The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 2, 2006, Pages 219-228

  Pauwels, Bea ^a   Korst, Annelies E C ^a   Lambrechts, Hilde A J ^a   Pattyn, Greet G O ^a   De Pooter, Christel M J ^b   Lardon, Filip ^a   Vermorken, Jan B ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

Difluorodeoxyuridine; Gemcitabine; Radiosensitisation; Radiotherapy

Indexed keywords

CASPASE 3; DEAMINASE; DEOXYCYTIDINE DEAMINASE; DIFLUORODEOXYURIDINE; DRUG METABOLITE; FLOXURIDINE DERIVATIVE; GEMCITABINE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMORADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE S PHASE; CELL STRAIN; CELL STRAIN ECV304; CELL STRAIN H292; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE ENHANCEMENT FACTOR; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME DEGRADATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; STAINING;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FLOXURIDINE; HUMANS; RADIATION-SENSITIZING AGENTS;

EID: 33646479901     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0158-5     Document Type: Article

References (47)

1. Abbruzzese JL, Grunewald R, Weeks Ea, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
2. Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pined HM, Peters GJ (2000) Cross-resistance in the 2′,2′- difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. European Journal of Cancer 36:1974-1983
3. Brown J, Reading SJ, Jones S, Fitchett CJ, Howl J, Martin A, Longland CL, Michelangeli F, Dubrova YE, Brown CA (2000) Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 80:37-45
4. Cesario A, Margaritora S, Trodella L, Valente S, Corbo GM, Macis G, Galetta D, d'Angelillo RM, Porziella V, Ramella S, Mangiacotti MG, Granone P (2002) Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer. Lung Cancer 37:207-212
5. Chen M, Hough AM, Lawrence TS (2000) The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 45:369-374
6. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
7. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PWT, Lee JE, Lenzi R, Vauthey JN, Wong ABS, Phan T, Nguyen Q, Janjan NA (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293-1302
8. Dirks WG, MacLeod RA, Drexler HG (1999) ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross-contamination at source [letter]. In Vitro Cell Dev Biol Anim 35:558-559
9. Doyle TH, Mornex F, McKenna G (2001) The clinical implications of gemcitabine radiosensitization. Clin Cancer Res 7:226-228
10. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS (2001) Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792-799
11. Fertil B, Dertinger H, Courdi A, Malaise EP (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiation Res 99:73-84
12. Huang P, Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188
13. Huang P, Plunkett W (1995) Induction of apoptosis by gemcitabine. Semin Oncol 22:19-25
14. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T (2002) A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86:1551-1554
15. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ (1997) Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest 5:62-71
16. Korst AEC, Dyck J, Schrijvers D, Lardon F, Vermorken JB (2000) Phase I pharmacokinetic study of the combination of Gemcitabine, Vinorelbine and Cisplatin (GVP). Proceedings of the American Association for Cancer Research 41:705
17. de Lange SM, van Groeningen CJ, Meijer OWM, Cuesta MA, Langendijk JA, van Riel JMGH, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G (2002) Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 38:1212-1217
18. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ (1998) Radiosensitizing potential of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41:875-882
19. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach S (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro- 2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872
20. Lawrence TS, Davis MA, Hough A, Rehemtulla A (2001) The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidirne (gemcitabine)-mediated radiosensitization. Clin Cancer Res 7:314-319
21. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA (1996) Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 56:5198-5204
22. Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman KW, Ang KK (1999) Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44:1125-1135
23. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208
24. Merlin T, Brandner G, Hess RD (1998) Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. Int J Oncol 13:1007-1016
25. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107-114
26. Mohiuddin M, Kudrimou M, Regine WF, McGrath PC, Hanna N, John W (2002) Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: A phase I study. Cancer J 8:255-262
27. Mose S, Karapetian M, Juling Pohlit L, Taborski B, Damrau M, Ramm U, Rahn A, Bottcher HD (2000) Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res 20:401-405
28. Mose S, Class R, Weber HW, Rahn A, Brady LW, Bottcher HD (2003) Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 26:60-69
29. Ostruszka LJ, Shewach DS (2000) The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 60:6080-6088
30. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208:151-158
31. Pauwels B, Korst AEC, de Pooter CMJ, Lambrechts HAJ, Pattyn GGO, Lardon F, Vermorken JB (2003) The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. Eur J Cancer 39:838-846
32. Pauwels B, Korst AEC, de Pooter CMJ, Pattyn GGO, Lambrechts HAJ, Baay MFD, Lardon F, Vermorken JB (2003) Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 51:221-226
33. Pauwels B, Korst AEC, Lambrechts HAJ, Pattyn GGO, Van Bockstaele DR, Vermeulen K, Lenjou M, De Pooter CMJ, Vermorken JB, Lardon F (2003) Role of cell cycle effects and apoptosis in the radiosensitizing mechanism of gemcitabine. Proc Am Ass Cancer Res 2:R5120a
34. Pauwels B, Korst AEC, Pattyn GGO, Lambrechts HAJ, Van Bockstaele DR, Vermeulen K, Lenjou M, De Pooter CMJ, Vermorken JB, Lardon F (2003) Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57:1075-1083
35. Pauwels B, Korst AEC, Andriessen V, Baay MFD, Pattyn GGO, Lambrechts HAJ, De Pooter CMJ, Lardon F, Vermorken JB (2005) Unravelling the mechanism of radiosensitisation by gemcitabine: the role of p53. Radiat Res (in press)
36. Peters GJ, Ruiz van Haperen VWT, Bergman AM, Veerman G, Smitskamp-Wilms E, Van Moorsel CJA, Kuiper CM, Braakhuis BJM (1996) Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23:16-24
37. Pipas JM, Mitchell SE, Barth RJ, Vera Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP, Amer Brachytherapy Soc (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50:1317-1322
38. Robinson BW, Shewach DS (2001) Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 7:2581-2589
39. Rockwell S, Grindley GB (1992) Effect of 2′-2′- difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncology Research 4:151-155
40. Rosier JF, Beauduin M, Bruniaux M, De Bast M, De Coster B, Octave Prignot M, Scalliet P, Gregoire V (1999) The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol 75:245-251
41. Shewach DS, Lawrence TS (1996) Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14:257-263
42. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223
43. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
44. Storniolo AM, Allerheiligen SRB, Pearce H (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:2-7
45. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D' Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N (2002) Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20:804-810
46. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327
47. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PWT, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253